Last $36.60 USD
Change Today +1.54 / 4.39%
Volume 595.5K
As of 8:10 PM 12/26/14 All times are local (Market data is delayed by at least 15 minutes).

nps pharmaceuticals inc (NPSP) Snapshot

Open
$35.07
Previous Close
$35.06
Day High
$36.61
Day Low
$35.00
52 Week High
02/25/14 - $39.68
52 Week Low
04/15/14 - $22.11
Market Cap
3.9B
Average Volume 10 Days
1.5M
EPS TTM
$0.0065
Shares Outstanding
106.8M
EX-Date
--
P/E TM
5,650.8x
Dividend
--
Dividend Yield
--
Current Stock Chart for NPS PHARMACEUTICALS INC (NPSP)

nps pharmaceuticals inc (NPSP) Related Businessweek News

View More BusinessWeek News

nps pharmaceuticals inc (NPSP) Details

NPS Pharmaceuticals, Inc., a biopharmaceutical company, engages in the development of therapeutic products in the United States. Its lead product is Gattex for the treatment of adult patients with short bowel syndrome (SBS) who are dependent on parenteral support. The company also develops Natpara that is under Phase 3 clinical trial for the treatment of adult hypoparathyroidism; NPSP790 and NPSP795 calcilytic compounds, which are in Phase 1 clinical trial for application in rare disorders involving increased calcium receptor activity, such as autosomal dominant hypocalcemia with hypercalciuria; and Teduglutide that is under preclinical stage for pediatric indications. It has collaborative agreements with GlaxoSmithKline to collaborate on the research, development, and commercialization of calcium receptor active compounds to treat osteoporosis and other bone metabolism disorders; and Kyowa Hakko Kirin Co. Ltd. to develop and commercialize compounds for the treatment of hyperparathyroidism. The company was founded in 1986 and is based in Bedminster, New Jersey.

207 Employees
Last Reported Date: 02/18/14
Founded in 1986

nps pharmaceuticals inc (NPSP) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $600.0K
Chief Financial Officer and Executive Vice Pr...
Total Annual Compensation: $413.7K
Senior Vice President and President of NPS Ph...
Total Annual Compensation: $395.0K
Chief Medical Officer and Executive Vice Pres...
Total Annual Compensation: $407.9K
Vice President of Corporate Development & Str...
Total Annual Compensation: $223.1K
Compensation as of Fiscal Year 2013.

nps pharmaceuticals inc (NPSP) Key Developments

Shire Reportedly Eyes NPS And Other Targets

Shire plc (LSE:SHP) intends to acquire NPS Pharmaceuticals, Inc. (NasdaqGS:NPSP). Shire is considering an offer for NPS, Bloomberg reported, citing people familiar with the matter. The timing of a possible bid would depend on whether the U.S. Food and Drug Administration approve NPS's Natpara, two of the people told Bloomberg. Shire is seeking other targets as well, Bloomberg said. Reuters added that Shire and NPS were not immediately available for comment. Shares of Shire rose 1.3% while that of NPS rose 23% to $37.5.

NPS Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:45 AM

NPS Pharmaceuticals, Inc. Presents at Oppenheimer 25th Annual Healthcare Conference, Dec-11-2014 09:45 AM. Venue: The Crowne Plaza Hotel, New York, New York, United States. Speakers: Luke M. Beshar, Chief Financial Officer, Principal Accounting Officer and Executive Vice President.

NPS Pharmaceuticals, Inc. Receives Japanese Ministry of Health, Labor and Welfare Grants Teduglutide Orphan Drug Designation for the Treatment of Short Bowel Syndrome

NPS Pharmaceuticals, Inc. announced that the Japanese Ministry of Health, Labor and Welfare has granted teduglutide orphan drug designation for the treatment of Short Bowel Syndrome (SBS). Also, due to the strong medical need for SBS treatments in Japan, the MHLW's expert committee on Unapproved New Drugs and New Indications with High Medical Needs requested that NPS Pharma Japan K.K. develop teduglutide for adult SBS earlier this year. To meet local regulatory requirements, the company is also preparing to initiate a small study in Japanese patients with SBS before the end of this year. In Japan, orphan drug status can be bestowed on drugs or medical devices intended for use in fewer than 50,000 patients for which there is a high medical need. Orphan drugs may be eligible for subsidies and tax credits to reduce the burden of product development, priority consultation and review for marketing authorization, and an extended reexamination period of up to 10 years. The MHLW established the committee on Unapproved New Drugs and New Indications with High Medical Needs to enhance the development of drugs and indications that have been approved for use in the United States and Europe, but are not yet approved in Japan. Due to the strong medical need for SBS treatments in Japan, the committee determined that teduglutide met these criteria and requested that the company develop the drug for adult SBS. Teduglutide received orphan drug designation for the treatment of SBS from the U.S. Food and Drug Administration in 2000 and the European Medicines Agency in 2001. In the U.S., NPS Pharma markets teduglutide under the trade name Gattex and in the EU, as Revestive.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
NPSP:US $36.60 USD +1.54

NPSP Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for NPSP.
View Industry Companies
 

Industry Analysis

NPSP

Industry Average

Valuation NPSP Industry Range
Price/Earnings 100.0x
Price/Sales 18.5x
Price/Book 29.9x
Price/Cash Flow 3,767.2x
TEV/Sales 17.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact NPS PHARMACEUTICALS INC, please visit www.npsp.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.